
Funda Meric-Bernstam, MD, discusses the outcomes of the FONTANA trial of an investigational folate receptor alpha–targeting antibody-drug conjugate in platinum-resistant ovarian cancer.

Funda Meric-Bernstam, MD, discusses the outcomes of the FONTANA trial of an investigational folate receptor alpha–targeting antibody-drug conjugate in platinum-resistant ovarian cancer.

Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in endometrial cancer.

Estelamari Rodriguez, MD, MPH, explains why patients with advanced non-small cell lung cancer (NSCLC) and high programmed death ligand 1 (PD-L1) expression should not start immunotherapy while biomarker results are pending, since ROS1-positive disease responds poorly to it.

Julia K. Rotow, MD, explains how RNA-based next-generation sequencing (NGS) fits into testing for newly diagnosed advanced nonsquamous non-small cell lung cancer (NSCLC) in a discussion moderated by Matthew A. Gubens, MD, MS, with panelists Estelamari Rodriguez, MD, MPH, and Ana I. Velázquez Mañana, MD, MSc.

Domenica Lorusso, MD, PhD, discusses phase 3 findings on sacituzumab tirumotecan in advanced or recurrent endometrial cancer.

Brian M. Slomovitz, MD, discusses the outcomes of the KEYNOTE-C93 trial of pembrolizumab for endometrial cancer.

Tamim Niazi, MDCM, discusses key findings from the phase 3 DASL-HiCaP study presented at the 2026 ESMO Congress.

Dr Jacob Sands discusses first-look OS and PFS data for tarlatamab plus durvalumab maintenance from the phase 3 DeLLphi-305 trial at ESMO 2026.

Marcelo Vailati Negrao, MD, discusse safety outcomes with first-line olomorasib plus chemoimmunotherapy in LOXO-RAS-20001 and SUNRAY-01.

John Bridgewater, BA, MBBS, MRCP, PhD, discusses the potential impact of the phase 3 HARMONi-GI1 trial on treating advanced biliary tract cancer.

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as first-line maintenance in SCLC.

Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.

Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Rahul Winayak, MD, explains new mRCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome immunotherapy resistance.

Darren Feldman, MD, discusses phase 1 data showing ixotatug vedotin drives notable responses in heavily pretreated germ cell tumors, with manageable ADC safety and potential phase 2 plans.

Shannon Westin, MD, MPH, weighs in on B7-H4 ADCs in gynecologic cancers, focusing on testing, toxicity in maintenance use, and sequencing amid resistance, target shifts, and expanding options.

Hannah Naughton, MD, explains how de-escalating surgery and chemotherapy in breast cancer expands breast conservation and improves quality of life.

Sherry Shen, MD, explains why invasive lobular breast cancer needs histology-specific clinical trials and how its unique biology shapes care.

Matthew Gubens, MD, explains how targeted therapies are moving into earlier-stage NSCLC, while molecular testing and resistance profiling guide treatment.

Matthew Gubens, MD, MS, explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic non–small cell lung cancer.

Real-world ARAAT results show darolutamide plus ADT/docetaxel may offer steroid-free triplet benefits over abiraterone triplet in mHSPC.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses how community oncologists should counsel and manage adverse events (AEs) with subcutaneous amivantamab in head and neck squamous cell carcinoma.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, characterizes the safety and tolerability of subcutaneous amivantamab monotherapy in cohort 1 of the OrigAMI-4 study.

Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy for rectal cancer and when watch-and-wait is feasible.

Four oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.

J. Thaddeus Beck, MD, discusses clinic logistics, patient preferences, and the future of on-body applicators as oncology shifts from intravenous to subcutaneous delivery.

Rethink trial design with decentralized, community-based models to cut barriers, let patients enroll closer to home, and preserve high-quality safety data.

Ashley Rosko, MD, discusses how telehealth can improve access to myeloma transplant evaluation, reduce care disparities, and address implementation barriers.

Dr Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.

In this episode of The OncoloGIST, myeloma experts discuss the abstracts they most anticipated at IMS 2026, including EXCALIBER-RRMM and PERSEUS.